KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pacira BioSciences (PCRX) EBITDA: 2009-2024

Historic EBITDA for Pacira BioSciences (PCRX) over the last 16 years, with Dec 2024 value amounting to -$73.4 million.

  • Pacira BioSciences' EBITDA rose 104.56% to $6.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $41.6 million, marking a year-over-year increase of 164.02%. This contributed to the annual value of -$73.4 million for FY2024, which is 183.69% down from last year.
  • Latest data reveals that Pacira BioSciences reported EBITDA of -$73.4 million as of FY2024, which was down 183.69% from $87.7 million recorded in FY2023.
  • In the past 5 years, Pacira BioSciences' EBITDA registered a high of $89.9 million during FY2021, and its lowest value of -$73.4 million during FY2024.
  • For the 3-year period, Pacira BioSciences' EBITDA averaged around $24.8 million, with its median value being $60.0 million (2022).
  • In the last 5 years, Pacira BioSciences' EBITDA spiked by 342.27% in 2020 and then slumped by 183.69% in 2024.
  • Over the past 5 years, Pacira BioSciences' EBITDA (Yearly) stood at $46.4 million in 2020, then soared by 94.01% to $89.9 million in 2021, then crashed by 33.25% to $60.0 million in 2022, then spiked by 46.07% to $87.7 million in 2023, then slumped by 183.69% to -$73.4 million in 2024.